How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Crizanlizumab for preventing sickle cell crises in sickle cell disease

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about crizanlizumab

Marketing authorisation indication

Crizanlizumab (Adakveo, Novartis) is indicated 'for the prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged 16 years and older. It can be given as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or as monotherapy in patients for whom HU/HC is inappropriate or inadequate'.

Dosage in the marketing authorisation

The dosage schedule will be available in the summary of product characteristics.

Price

The list price of crizanlizumab is confidential. The company has a commercial arrangement, which would have applied if the technology had been recommended.